Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesEFNA1 ligand and its receptor EphA2: Potential biomarkers for hepatocellular carcinoma
International Journal of Cancer, 11/09/09
Cui XD et al. – Novel biomarkers are needed for early detection and progression evaluation of hepatocellular carcinoma (HCC).The purpose of this study was to identify useful biomolecular markers for HCC. The 26 genes that encode EFNA1 and EphA2 may be useful serum markers for the detection of HCC development and progression, respectively.
Methods- 26 genes that encode membrane or secretory proteins identified from cDNA microarray data
- Examined expression of EFNA1 and its receptor EphA2 and determined biological implications during development and progression of HCC
- EFNA1 mRNA overexpressed in most HCCs as compared with expression in corresponding nontumor tissues (36 out of 40 cases, 90%), but EphA2 expression was noted in only half of HCC tissues (20 of 40 cases, 50%)
- In most hepatoma cell lines, the EFNA1 protein expression was positively associated with alpha-fetoprotien (AFP) expression but inversely associated with EphA2 expression
- EFNA1 levels detectable in supernatant of cultured hepatoma cells and in serum of patients with HCC
- EphA2 expression prominent in highly invasive hepatoma cells, and its overexpression significantly correlated with decreased differentiation (r = 0.0248) and poor survival for HCC patient
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia
Haematologica, 12/20/09
The mitogen-activated protein kinase signaling pathways: role in megakaryocyte differentiation
Journal of Thrombosis and Haemostasis, 12/20/09
Reprogramming T Lymphocytes for Melanoma Adoptive Immunotherapy by T-Cell Receptor Gene Transfer with Lentiviral Vectors
Cancer Research, 12/20/09
Today in GI Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer
Investigational New Drugs, 12/18/09
Anemia response and safety to epoetin-beta treatment in patients with neoadjuvant therapy prior to primary digestive tract tumor surgery
Cancer Chemotherapy and Pharmacology, 12/17/09
Decreased expression of KLF6 and its significance in gastric carcinoma
Medical Oncology, 12/17/09
Sponsor
Article Search
Sponsor
Sponsor